In this study it will be analyzed how often the sleep apnea syndrome can be observed in patients with newly diagnosed lung cancer with the help of ApneaLink device by ResMed.
Determination of the SAS- frequence in patients with bronchial carcinoma. The patients will be screened at home for 1 night with the ApneaLink device by ResMed. The apneaLink device is a standard screening tool for sleep apnea in clinical practice.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
100
ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
Medizinische Klinik I Uniklinik RWTH Aachen
Aachen, North Rhine-Westphalia, Germany
RECRUITINGKrankenhaus Merheim
Cologne, North Rhine-Westphalia, Germany
RECRUITINGFlorence-Nightingale Hospital
Düsseldorf, Germany
RECRUITINGpercent of sleep apnea in patients with bronchial carcinoma
The percent of sleep apnea in a cohort of patients with bronchial carcinoma will be evaluated. The duration of the study participation is two days.
Time frame: two days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.